Q1 YTD/FY2025 Financial Results

from the beginning

Q1 YTD/FY2025 Financial Results

Cautionary Statement Regarding Forward-Looking Information

Q1 YTD/FY2025 Overview

Agenda

• Q1 YTD/FY2025 Financial Results

• Q1 YTD/FY2025 Financial Results: Main Brands

• IZERVAY: Business Update (US)

• PADCEV&VYLOY: Business Update

• Q1 YTD/FY2025 Financial Results: Cost Items

Agenda

• Strategic Brands: FY2025 Key Expected Events

• Progress in Focus Area Approach

• Progress in Primary Focus Targeted Protein Degradation

• Progress in Focus Area Approach: ASP7317 (Blindness & Regeneration)

• Exclusive License Agreement with Evopoint

• Portfolio of Claudin 18.2-Targeted Therapies

• Key Takeaways

Appendix

• Strategic Brands: Potential Peak Sales (as of Jul 2025)

• Capital Allocation

• Q1 YTD/FY2025 Actual: FX Rate

• FY2025 Forecast: FX Rate & FX Sensitivity

• Balance Sheet & Cash Flow Highlights

• Balance of Bonds and Borrowings Highlights

• Main Intangible Assets (as of Jun 30, 2025)

• Sustainable Margin Transformation

• Lifecycle Management of Strategic Brands

• Progress in Focus Area Approach:Current Status of Programs in Clinical Trial

• Overview of Primary Focus Flagship Programs (1/2)

• Overview of Primary Focus Flagship Programs (2/2)

• Robust Pipeline of Astellas

• Progress in Overall Pipeline

• Strategic Brands: Status Update

• enfortumab vedotin (EV) (1/5): Nectin-4 Targeted ADC Overview of Development

• enfortumab vedotin (EV) (2/5): Clinical Studies

• enfortumab vedotin (EV) (3/5): Study Data by Disease Stage of UC

• enfortumab vedotin (EV) (4/5): Study Data in 1L mUC (EV-302)

• enfortumab vedotin (EV) (5/5): Development for Muscle-invasive bladder cancer (MIBC)

• avacincaptad pegol (ACP): Complement C5 Inhibitor / Pegylated RNA Aptamer

• fezolinetant: NK3 receptor antagonist

• zolbetuximab: Anti-Claudin 18.2 Monoclonal Antibody

• gilteritinib: FLT3 Inhibitor

• enzalutamide (1/2): Androgen Receptor Inhibitor

• enzalutamide (2/2): Phase 3 Study Data by Disease Stage

On the forefront of healthcare changeto turn innovative scienceinto VALUE for patients

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8